Search results for "Clopidogrel resistance"

showing 2 items of 2 documents

Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry

2017

The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians because of its frequency and the severity of adverse events related to it. The identification of patients with high platelet reactivity (HPR may help to improve their therapy applying the concept of personalized medicine, most important in the older people treated with polypharmacy. The existece of such a simple clinical method as the STIB score, that allows to predict the possible resistace to clopidogrel at the bedside without using expensive laboratory investigations, provides an attractive approach to the problem.

Blood Plateletsmedicine.medical_specialtyTiclopidineSettore MED/09 - Medicina InternaHPRTreatment outcomeMEDLINEClopidogrel resistance030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinePrevalenceInternal MedicinemedicineClopidogrel resistance HPR STIB score REPOSIHumansIn patientPlateletRegistriesSTIB score030212 general & internal medicineTiclopidineClopidogrel resistance; HPR; REPOSI; STIB score; Internal Medicinebusiness.industryClopidogrel resistanceREPOSISurgeryTreatment OutcomePlatelet aggregation inhibitorbusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.

2014

Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1 modify effect of such dose-adjustment strategy.Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off value of ≥60% was defined as hyporesponsiveness. Polymorphism of two cytochromes (CYP2C19, CYP2C9) and gene ABCB1 were determined. …

CYP2C9MaleMedicine (General)ATP Binding Cassette Transporter Subfamily BTiclopidinemedicine.medical_treatmentCYP2C19PharmacologyR5-920Percutaneous Coronary InterventionmedicinePotencyHumansProspective StudiesCYP2C19AlleleCYP2C9AllelesAgedCytochrome P-450 CYP2C9Medicine(all)Polymorphism GeneticDose-Response Relationship Drugbusiness.industryClopidogrel resistanceMicrofilament ProteinsPercutaneous coronary interventionABCB1Drug-Eluting StentsVASPMiddle AgedClopidogrelPhosphoproteinsClopidogrelCytochrome P-450 CYP2C19Drug-eluting stentPharmacogeneticsAutomotive EngineeringConventional PCIFemalebusinessCell Adhesion MoleculesPlatelet Aggregation InhibitorsClopidogrel resistance; VASP; CYP2C19; ABCB1; CYP2C9medicine.drugMedicina (Kaunas, Lithuania)
researchProduct